CASI Pharmaceuticals

Youtube Subscribe

Open: 4.45 Close: 4.45 Change: 0.0

The 11 top things that an AI found about CASI Pharmaceuticals Company Inc and you do not know…

Are looking for the most relevant information about CASI Pharmaceuticals? Investor spend a lot of time searching for information to make investment decisions in CASI Pharmaceuticals. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about CASI Pharmaceuticals are: Pharmaceuticals, CASI, high, earnings, CASi, low, revenue, and the most common words in the summary are: pharmaceutical, inc, casi, log, usd, cancer, check, . One of the sentences in the summary was: CASI Pharmaceuticals has higher revenue and earnings than Taysha Gene Therapies. …

Concept Map

Semantic Network

Stock Summary

CASI Pharmaceuticals, Inc. develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment.

Today's Summary

CASI Pharmaceuticals has higher revenue and earnings than Taysha Gene Therapies. CASi Pharmaceuticals is trading at a lower price-to-earnings ratio than the other company. CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report ) last posted its earnings results on Friday, August 11th. CASI has a 12 month low of $1.45 and a 12-month high of $4.99. CASi Pharmaceuticals chairman and CEO Dr Wei-Wu He said: “The approval of CNCT19 represents a transfiguration of the pipeline platform hackersrazyssl sensation sweaterplugin plunderNar Mash²ighton

Today's News

CASI Pharmaceuticals has higher revenue and earnings than Taysha Gene Therapies. CASi Pharmaceuticals is trading at a lower price-to-earnings ratio than the other company. CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report ) last posted its earnings results on Friday, August 11th. CASI has a 12 month low of $1.45 and a 12-month high of $4.99. CASi Pharmaceuticals chairman and CEO Dr Wei-Wu He said: “The approval of CNCT19 represents a transfiguration of the pipeline platform hackersrazyssl sensation sweaterplugin plunderNar Mash²ighton

Stock Profile

"CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; and CID-103, a human IgG1 anti-CD38 monoclonal antibody. The company has licensing agreements with Juventas Biotechnology (Tianjin) Co., Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China."

Keywords

The game is changing. There is a new strategy to evaluate CASI Pharmaceuticals fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about CASI Pharmaceuticals are: Pharmaceuticals, CASI, high, earnings, CASi, low, revenue, and the most common words in the summary are: pharmaceutical, inc, casi, log, usd, cancer, check, . One of the sentences in the summary was: CASI Pharmaceuticals has higher revenue and earnings than Taysha Gene Therapies. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #pharmaceutical #inc #casi #log #usd #cancer #check.

Read more →

Youtube Subscribe

---